X-energy jumped 11.7% on a quarter where operating expenses ran three times the top line

by Priya Raghunathan · August 14, 2026

Mid-Cap Companies Reporter, The SmallCap Signal

X-energy (Nasdaq: XE) closed Thursday at $22.73, up 11.70%, according to StockAnalysis data, in a session where the Russell 2000 gained 0.24% and the S&P 500 rose 0.65%, per the Associated Press. The move followed the company's second-quarter results, released before the opening bell. At roughly $9.24 billion of market capitalisation on about 406.4 million shares, X-energy sits in mid-cap territory, but its financial profile has more in common with the developmental small caps further down the index.

The reported growth was genuine. Total revenues and grant income were $54.6 million in the second quarter against $21.5 million a year earlier, an increase of 154%, according to the company's release. For the first six months, the figure was $98.0 million versus $42.3 million, up 132%.

That line item needs unpacking. X-energy reports revenue and grant income together, which means the top line blends commercial receipts with government-supported development funding rather than measuring product sales. The split is disclosed: of the $54.6 million in the quarter, $50.1 million was services revenue and $4.5 million was grant income, and across six months it was $90.0 million against $8.0 million. Grants are the smaller share of the two, but the larger share is development and services work on reactors that are not yet in commercial operation, not sales of an operating product. The company also said it received formal approval of its Advanced Reactor Demonstration Program continuation application from the Department of Energy, extending its budget period through March 2027 on a 50/50 cost-share basis.

Operating expenses ran far ahead of it. X-energy reported $164.6 million of operating expenses in the quarter, up 156% year over year, and $274.2 million across the six months, up 146%. Net loss attributable to X-energy for the first half was $59.1 million. Spending is growing at least as fast as the income that offsets it, which is what a pre-commercial company scaling manufacturing capacity looks like on paper.

The balance sheet is why the market can absorb that. X-energy reported $1.1 billion in cash and equivalents and $1.9 billion of total liquidity including short- and long-term investments, with no debt outstanding. That position is largely a product of the company's initial public offering, which closed on April 27, 2026 and raised roughly $1.1 billion in net proceeds. This was, in other words, X-energy's first quarterly report as a public company — the offering closed part-way through the period — and it reported with a war chest most companies at this stage of development never assemble.

The quarter's operational disclosures were all supply-chain and site items rather than revenue items. X-energy said it secured long-term high-assay low-enriched uranium enrichment agreements with Centrus Energy and General Matter, agreed to invest up to $8 million in milestone-based payments with SGL Carbon to double European graphite capacity by 2030 and support production for up to eight Xe-100 reactors a year, received an $11 million economic development grant from Tennessee for its TRISO-X fuel campus, and acquired roughly 70 acres adjacent to its Oak Ridge facility, expanding the site to about 180 acres. It also extended a research partnership with Oak Ridge National Laboratory through a 30-month cooperative research and development agreement, and said it was named a founding member of Project Prometheus, an artificial-intelligence research effort alongside Idaho National Laboratory, NVIDIA and AWS, with $10 million of committed private capital.

Chief executive J. Clay Sell said the quarter "reflects our continued focus on execution across every part of our business." In a separate comment in the same release he tied the supply-chain items together: "We are investing in capabilities that better position the company for commercial execution and scale. Our HALEU enrichment service agreements meaningfully de-risk a substantial portion of the deployment of our reactors, and the agreement with SGL secures our access to critical graphite components, enabling our strategy to build reactors at scale."

The company describes a project pipeline of 144 reactors across the United States and the United Kingdom, representing roughly 11.5 gigawatts of electric capacity, anchored by Dow, Amazon and Centrica. A pipeline is a statement of intent, not a contracted order book, and the gap between the two in advanced nuclear has historically been measured in years and regulatory approvals rather than quarters.

The risks here should be stated without decoration. X-energy has no reactors in commercial operation, no debt but also no path to positive operating cash flow disclosed in this release, and a top line that depends materially on government programmes whose funding is appropriated rather than contracted. StockAnalysis records a 2025 net loss of $389.78 million and a 52-week trading range of $13.29 to $37.10 — a spread of nearly three times low to high, which is a fair description of how uncertain the market is about what this business is worth. A rally of 11.7% in one session on a quarter that disclosed no operating reactors and a materially wider loss is a sentiment move.

X-energy is the largest example of a pattern running through this earnings week: small and mid caps whose valuations rest on a dated future event rather than a current income statement. The clearest small-cap version reported after Thursday's close. Capricor Therapeutics (Nasdaq: CAPR) posted no revenue for the first half of 2026 and a second-quarter net loss of $40.7 million, or $0.70 per share, with $237.9 million of cash and equivalents at June 30, down from $318.1 million at the end of 2025. The company said its funds are sufficient to meet operating capital requirements for at least the next twelve months.

Capricor's near-term value is concentrated in a single date. An FDA advisory committee voted 3 to 9, with no abstentions, against the proposition that available evidence supports the effectiveness of its cell therapy deramiocel for cardiomyopathy in Duchenne muscular dystrophy — a narrower indication than the company had proposed — according to Capricor's own late-July update. The committee's feedback in a separate discussion was, in the company's words, directionally supportive of the Phase 3 HOPE-3 evidence including the primary endpoint. The vote is non-binding, and the FDA's target action date is August 22, 2026. Capricor closed Thursday at $4.21 for a market capitalisation of about $243.8 million, with short interest at 27.6% of shares outstanding and the stock down 47.6% over 52 weeks, per StockAnalysis. A binary regulatory decision eight days out, against that level of short positioning, is a setup that can move violently in either direction.

The two companies sit at opposite ends of the same problem. X-energy has capitalised itself so heavily that its milestone risk is spread over a decade and cushioned by $1.9 billion of liquidity. Capricor has concentrated its into a single agency decision this month. Investors in either are underwriting an event, not a cash flow, and should be clear-eyed that this is what they are doing.

Nothing in this article is investment advice, and neither company's outcome is predictable from the information currently disclosed.